Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Xiaowen Mao | Medicine and Health Sciences | Best Researcher Award

University of Macau | Macau

Dr. Xiaowen Mao, M.D., Ph.D., is an Assistant Professor at the State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, where she leads translational research on cancer biology, immunotherapy, and tumor microenvironment modulation. She earned her Ph.D. in Biomedical Sciences from the University of Hong Kong and her B.Sc. in Clinical Medicine from Shanghai Jiao Tong University, China. Her research focuses on extracellular vesicles, immune homeostasis, metabolic reprogramming in tumors, and hepatocellular carcinoma metastasis, integrating molecular, cellular, and translational approaches. Dr. Xiaowen Mao has led several high-impact projects as principal investigator, funded by the Health and Medical Research Fund, National Natural Science Foundation Young Scientist Fund, and FDCT Innovation and Technology Promotion. Her significant contributions include the development of broadly potent neutralizing antibodies targeting Nidogen 1 to inhibit tumor growth, elucidation of extracellular vesicle-mediated metabolic reprogramming in tumors, and advances in dendritic cell vaccine strategies. She holds a U.S. patent on Nidogen 1 as a diagnostic and therapeutic target for hepatocellular carcinoma, serves as Guest Editor for Frontiers in Endocrinology, and is an ad-hoc reviewer for multiple high-impact journals. According to Scopus, she has 31 publications, 1,114 citations by 1,010 documents, and an h-index of 20. Dr. Xiaowen Mao’s work bridges fundamental research and clinical translation, delivering innovative therapies and advancing precision medicine in oncology, while demonstrating a profound impact on cancer biology, immunotherapy, and translational research.

Profile: Scopus

Featured Publications

  • Xue, T. M., Yeung, C. L. S., Mao, X. W., Tey, S. K., Lo, K. W., Tang, H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of Translational Internal Medicine. https://doi.org/10.1515/jtim-2025-0008

  • Xia, L., Li, C. G., Zhao, J., Sun, Q. C., & Mao, X. W.* (2025). Rebalancing immune homeostasis in combating disease: The impact of medicine food homology plants and gut microbiome. Phytomedicine, 136, 156150. https://doi.org/10.1016/j.phymed.2025.156150

  • Chen, Z., Yam, J. W. P., & Mao, X. W.* (2024). The multifaceted roles of small extracellular vesicles in metabolic reprogramming in the tumor microenvironments. Proteomics, e2300021. https://doi.org/10.1002/pmic.202300021

  • Lee, K. W., Yam, J. W. P., & Mao, X. W.* (2023). Dendritic cell vaccines: A shift from conventional approach to new generations. Cells, 12(2147). https://doi.org/10.3390/cells12172147

  • Li, S., Delvecchio, M., Ramkumar, K., Mao, X. W., Sun, X. D., & Guo, S. Z. (2023). Editorial: Clinical and genetic determinants of diabetes and complications. Frontiers in Endocrinology.

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Published on by Forensic Scientist

Dr. Zengxin Gao | Medicine and Health Sciences | Innovative Research Award

Department of Orthopedics, Zhongda Hospital, Southeast University School of Medicine | China

Dr. Zengxin Gao is a highly accomplished Chief Physician at Southeast University, Affiliated Zhongda Hospital, recognized for his expertise in orthopedics and minimally invasive spinal interventions. He completed his PhD in Orthopedics at Peking Union Medical College in 2008, following a Master’s degree in Orthopedics (2005) and a Bachelor’s degree in Clinical Medicine from Nanjing Medical University (1990). Dr. Zengxin Gao’s clinical career spans over 30 years, beginning as a physician at Nantong University Affiliated Dongtai Hospital, advancing to attending and associate chief physician, and currently serving as Chief Physician at Southeast University Affiliated Zhongda Hospital since 2015. His research focuses on spinal surgery, intervertebral disc regeneration, and innovative minimally invasive techniques for chronic low back and leg pain, particularly in elderly patients. He has led notable projects, including the Jiangsu Provincial Health Commission’s New Technology Introduction Project on percutaneous single-axis hole microscopy (2021–2023). Dr. Zengxin Gao has made significant scholarly contributions, including sole corresponding authorship in Wenbin Xuan, Yucheng Gao, Zengxin Gao. Intraspinal Bone Fragments Resorption in Thoracolumbar Burst Fracture. JAMA Neurol. 2023;80(11):1248–1249 [Cited 12]; co-first authorship in Linhui Ye, Zengxin Gao, Saeed Rohani. Intervertebral disk regeneration in a rat model by allopurinol-loaded Chitosan/alginate hydrogel. Biomol Biomed. 2023;23(4):661–670 [Cited 5]; and co-corresponding authorship in Shuhua Fang et al. Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskelet Disord. 2024;25:5 [Cited 3]. He has been awarded the Provincial and Ministerial First Prize for the Medical New Technology Introduction Award (2022) for pioneering percutaneous transforaminal endoscopic intervertebral fusion. Dr. Zengxin Gao’s combination of clinical expertise, innovative research, and leadership in orthopedics underscores his outstanding contributions and makes him an ideal candidate for the Innovative Research Award.

Profile: Scopus

Featured Publications

• Xuan, W., Gao, Y., & Gao, Z. (2023). Intraspinal bone fragments resorption in thoracolumbar burst fracture. JAMA Neurology, 80(11), 1248–1249.
https://doi.org/10.1001/jamaneurol.2023.2901

• Ye, L., Gao, Z., & Rohani, S. (2023). Intervertebral disk regeneration in a rat model by allopurinol-loaded chitosan/alginate hydrogel. Biomolecules and Biomedicine, 23(4), 661–670.
https://doi.org/10.17305/bjbms.2023.8535

• Fang, S., Cao, D., Wu, Z., Chen, J., Huang, Y., Shen, Y., & Gao, Z. (2024). Circ_0027885 sponges miR-203-3p to regulate RUNX2 expression and alleviates osteoporosis progression. BMC Musculoskeletal Disorders, 25(1), 5.
https://doi.org/10.1186/s12891-023-07172-0

• Gao, Z., Lin, Y., Wu, Z., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2020). LncRNA SNHG6 can regulate the proliferation and apoptosis of rat degenerate nucleus pulposus cells via regulating the expression of miR-101-3p. European Review for Medical and Pharmacological Sciences, 24(16), 8251–8262.
https://doi.org/10.26355/eurrev_202008_22592

• Gao, Z., Lin, Y., Zhang, P., Cheng, Q., Ye, L., Wu, F., Chen, Y., Fu, M., Cheng, C., & Gao, Y. (2019). Sinomenine ameliorates intervertebral disc degeneration via inhibition of apoptosis and autophagy in vitro and in vivo. American Journal of Translational Research, 11(9), 5956–5966.
https://www.ajtr.org/files/ajtr0094769.pdf

Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Published on by Forensic Scientist

Mr. Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Institute of Legal Medicine and Forensic Sciences of Valencia | Spain

Mr. Alfonso Colorado Casado de Amezúa is a highly respected forensic physician whose career demonstrates a profound commitment to advancing forensic science, medico-legal education, and public communication of specialized knowledge. Currently serving as Director of the Institute of Legal Medicine and Forensic Sciences of Valencia, he has built a distinguished professional record over more than fifteen years, holding key roles across Spain in Catalonia, Albacete, Cuenca, Guadalajara, and Valencia. His leadership has been pivotal in forensic pathology and disaster victim identification, where he has developed and applied protocols for managing mass casualty events with precision and compassion. Alongside his clinical and administrative responsibilities, Mr. Alfonso Colorado Casado de Amezúa has played a central role in training the next generation of forensic professionals. As adjunct professor at the University CEU-Cardenal Herrera in Valencia and Castellón, and as lecturer in numerous specialized courses for forensic doctors, law enforcement, and emergency response teams, he has demonstrated an exceptional ability to communicate complex forensic concepts with clarity and authority. His scientific contributions, including publications in the Revista Española de Medicina Legal and CorSalud, have provided valuable insights into sudden cardiac death and forensic practices in disaster contexts, strengthening both research and applied forensic work. As organizer and speaker in national training programs, he has further enhanced the visibility of forensic medicine and ensured the dissemination of best practices across Spain. By uniting research, practice, and communication, Mr. Colorado embodies the mission of forensic science to serve justice and society, making him an outstanding nominee for the Forensic Science Communication Award.

Profile: ORCID

Featured Publications

Colorado Casado de Amezúa, A., Garrido-Lestache López-Belmonte, E., & Giner Blasco, J. (2025). Medical forensic response during the flood in Valencia (Spain), October 29th, 2024 [Actuación médico-forense durante la riada en Valencia (España) el 29 de octubre de 2024]. Revista Española de Medicina Legal. Advance online publication.

Colorado, A., & Fernández Bayón, J. (2009). Síndrome de Loeys-Dietz. Diagnóstico diferencial en muerte súbita por disección aórtica. Revista Española de Medicina Legal, 35(2), 67–71.

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Prof. Zhiliang Xu | Medicine and Health Sciences | Best Researcher Award

Wannan Medical College | China

Prof. Zhiliang Xu, affiliated with Wannan Medical College, Wuhu, China, is a distinguished molecular biologist and epigenetics researcher whose work focuses on histone ubiquitination, chromatin remodeling, and their implications in neurological disorders, cancer, gametogenesis, and cellular reprogramming. He earned his Ph.D. from the State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences in 2017. According to Scopus, Prof. Zhiliang Xu has authored 11 publications, which have been cited 34 times, and he holds an h-index of 4, demonstrating the impact of his research in the scientific community. His seminal studies elucidated the role of H2B ubiquitination in chromatin relaxation during meiosis and cellular reprogramming, published in journals such as Nucleic Acids Research (2016), Cell Proliferation (2021), and Reproduction (2017). His recent work on neuronal repair, gut-liver axis regulation in diabetes, and genomic approaches to thalassemia has been featured in FASEB Journal (2025), Annals of Hematology (2025), and Neuroscience Letters (2025). Prof. Zhiliang Xu leads multiple high-impact national and provincial research projects, serves as a peer reviewer for journals including Scientific Reports and Neurochemical Research, and evaluates theses for graduate and doctoral candidates. Recognized with the 2021 National Maternal and Child Health Science and Technology Award (First Prize), the 2022 Guangzhou High-level Talent Award, and the 2024 Outstanding Young Talent honor in Anhui Province, Prof. Zhiliang Xu continues to advance fundamental understanding of chromatin biology and epigenetic regulation, exemplifying excellence, mentorship, and translational scientific impact, making him an outstanding candidate for the Best Researcher Award.

Profile: Scopus | ORCID

Featured Publications

1. Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025). Beyond transfusions and transplants: Genomic innovations rewriting the narrative of thalassemia. Annals of Hematology.

2. Zhang, Y., Wang, J., Huang, S., Liu, M., Zhao, Y., Xu, Z., & Zhu, X. (2025). Electroacupuncture preconditioning alleviates cortical neuronal injury in cerebral ischemia-reperfusion by rebalancing HES1 and NF-κB expression. Neuroreport.

3. Yan, X., Shi, L., Zhu, X., Zhao, J., Zhao, Y., Luo, J., Li, Q., & Xu, Z. (2025). From microbial homeostasis to systemic pathogenesis: A narrative review on gut flora’s role in neuropsychiatric, metabolic, and cancer disorders. Journal of Inflammation Research.

4. Huang, S., Lu, Y., Fang, W., Huang, Y., Li, Q., & Xu, Z. (2025). Neurodegenerative diseases and neuroinflammation-induced apoptosis. Open Life Sciences.

5. Li, Q., Zhang, L., Sun, Y., Du, Z., Xu, S., Wang, X., Wei, S., Tao, Y., Li, B., Jiang, J., Di, G., Huang, Y., & Xu, Z. (2025). p53 modulates the gut-liver axis via PI3K/AKT/Wnt signaling pathways in type 2 diabetes. FASEB Journal.

6. Li, Q., Yan, X., Zhao, Y., Xu, Z., & Zhu, X. (2025). Paeonol mitigates chronic stress-induced amygdalar neuronal damage through glycogen synthase kinase-3β/calcineurin axis regulation of synaptic plasticity. Neuroreport.

7. Zhu, X., Zhang, Y., Yan, X., Zhao, Y., Shi, L., Sun, Z., Meng, K., Zong, Y., Li, Q., & Xu, Z. (2025). Paeonol facilitates the repair of neuronal damage in the mPFC caused by chronic stress via the Rho GTPases-cofilin1 signaling pathway. Neuroscience Letters, 138329.

Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Mr. Zhechun Wu | Medicine and Health Sciences | Best Researcher Award

Chaoyang Hospital | China

Mr. Zhechun Wu is a resident physician in the Department of Urology at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, who has established himself as an emerging clinician–scientist combining medical training with impactful research. He earned his Bachelor of Science degree from Capital Medical University and is currently advancing his clinical expertise through residency while contributing to translational oncology research. His work is focused on prostate cancer, with particular emphasis on identifying therapeutic targets that regulate tumor immunity, a critical area for developing next-generation treatment strategies. Mr. Zhechun Wu has published in reputable international journals, including a recent article in Investigational New Drugs that explored drug targets modulating tumor immune response, a study that has already been cited in related scholarly work, reflecting its scientific significance. His projects are supported by competitive funding from the National Natural Science Foundation of China  and the Beijing Natural Science Foundation, highlighting his ability to secure prestigious grants and deliver research with clinical and academic value. Alongside research, his clinical practice in urology, oncology, and kidney transplantation strengthens his understanding of patient-centered challenges, allowing him to align laboratory findings with real-world medical needs. This dual role as physician and researcher equips him to contribute to both advancing cancer therapeutics and improving clinical outcomes, establishing a foundation for future leadership in medical innovation and academic research.

Profile: ORCID

Featured Publications

Zhang, Y., Qiu, X., Wu, Z., Li, Y., Shen, X., Wu, J., Cao, P., Sun, Z., & Wang, W. (2025). Comprehensive analysis of the association between volatile organic compound pollutants and chronic kidney disease in hypertensive populations: Insights from multi-omics approaches and identification of potential therapeutic targets. Environmental Research, 121966.

Wu, Z., Li, S., Li, Y., Wang, Z., & Wang, W. (2025). Identifying potential therapeutic targets for prostate cancer with mediating role in tumor immunity. Discover Oncology, 16, 98.

Wu, Z. (2025). Higher sexual frequency correlated with lowered PSA complex levels in U.S. men over 40 and without prostate conditions: A nationwide cross-sectional study. The Journal of Sexual Medicine.

Yan Bai | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Yan Bai | Medicine and Health Sciences | Best Researcher Award

Yunnan University | China

Dr. Yan Bai is a highly accomplished postdoctoral researcher at the State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan and the Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. She earned her PhD in Cell Biology from Yunnan University, MSc in Pharmacology from the Chinese PLA Medical Academy, and BSc in Pharmacy from Dali University, establishing a strong interdisciplinary foundation spanning pharmacology, microbiology, and cellular biology. Prior to her current role, she conducted research at the Chinese PLA General Hospital, focusing on combination therapies against multidrug-resistant bacteria. Her research primarily investigates mitochondrial homeostasis, tumor biology, and the molecular mechanisms underlying mitochondrial genetic diseases, with particular attention to mitochondria-associated condensates (MATOs) as regulators of protein translation and mitochondrial integrity. Dr. Yan Bai has led and contributed to several major research projects, including grants from the National Natural Science Foundation of China, the National Basic Research Program, and Yunnan Province Science and Technology initiatives. Her work has resulted in high-impact publications in journals such as Nature Aging (2025), Sci China Life Sci (2025), EMBO J (2024), and Biophys Rep (2024). According to Scopus, she has authored 10 publications, cited 177 times across 169 documents, with an h-index of 6, demonstrating both productivity and influence in her field. Through her interdisciplinary collaborations, innovative experimental approaches, and groundbreaking findings on mitochondrial regulation and aging, Dr. Yan Bai has made significant contributions to biomedical science, advancing understanding of mitochondrial biology, disease mechanisms, and translational biomedical applications.

Profile: Scopus

Featured Publications

Bai, Y., Ma, T., Zhao, S., Li, S., Wang, X., Li, J., Sun, W., Yang, Y., Liu, F., Shan, Q., Qin, Z., Liu, N., Zhang, J., Tian, F., Duan, M., Chen, S., Lai, F., Chen, Q., Wu, X., & Yang, C. (2025). Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. Nature Aging.

Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., & Sun, J. (2025). VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Science China Life Sciences, 68(7), 1996–2009.

Hao, Q., Dong, R., Bai, W., Chang, D., Yao, X., Zhang, Y., Xu, H., Li, H., Kui, X., Wang, F., Wang, Y., Wang, C., Lei, Y., Chen, Y., Shen, J., Sang, L., Bai, Y., & Sun, J. (2024). Screening for metastasis-related genes in mouse melanoma cells through sequential tail vein injection. Biophysical Reports, 10(1), 15–21.

Liu, F., Li, T., Gong, H., Tian, F., Bai, Y., Wang, H., Yang, C., Li, Y., Guo, F., Liu, S., & Chen, Q. (2024). Structural insights into the molecular effects of the anthelmintics monepantel and betaine on the Caenorhabditis elegans acetylcholine receptor ACR-23. EMBO Journal, 43(17), 3787–3806.

Wang, T., Zhou, X., Bai, Y., Zhang, L., Li, L., & Wu, C. (2018). Antiepileptic effect of uridine may be caused by regulating dopamine release and receptor expression in corpus striatum. Brain Research, 1688, 47–53.

Bai, Y., Liu, B., Wang, T., Cai, Y., Liang, B., Wang, R., Liu, Y., & Wang, J. (2015). In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1466–1471.

Liu, B., Bai, Y., Liu, Y., Di, X., Zhang, X., Wang, R., & Wang, J. (2015). In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Journal of Chemotherapy, 27(5), 271–276.

Fatemeh Shirani | Medicine and Health Sciences | Women Researcher Award

Published on by Forensic Scientist

Dr. Fatemeh Shirani | Medicine and Health Sciences | Women Researcher Award

Endocrine and Metabolism Research Center | Iran

Dr. Fatemeh Shirani is a distinguished scholar in the field of Nutritional Sciences, renowned for her groundbreaking contributions to clinical nutrition, dietary epidemiology, and metabolic health. She has consistently advanced the understanding of how diet and nutrition influence chronic disease prevention and treatment, with a strong emphasis on obesity, diabetes, and cardiovascular disease. Through her innovative research and global collaborations, she has established herself as a thought leader whose work bridges scientific evidence with practical dietary strategies for public health. Currently serving at the Endocrine and Metabolism Research Center of Isfahan University of Medical Sciences, she has become a role model for women in science through her dedication, mentorship, and international engagement.

Professional Profile

Google Scholar

ORCID

Education

Dr. Fatemeh Shirani completed her academic journey with distinction in Nutritional Sciences, earning her foundational and advanced degrees from leading Iranian institutions. She further enriched her expertise through doctoral-level research at Ahvaz Jundishapur University of Medical Sciences, where she focused on the intricate links between nutrition and chronic diseases. Her academic training was complemented by international research at Victoria University in Melbourne, Australia, where she deepened her skills in nutritional biomedicine and clinical research methodologies. This comprehensive educational background provided her with a strong platform to integrate theoretical knowledge with practical application in clinical and population-based nutrition research.

Experience

Dr. Fatemeh Shirani has accumulated extensive experience across research, teaching, and scientific service. She has contributed to large-scale community-based projects, such as national nutrition surveys and heart health programs, aimed at improving public health outcomes through evidence-based interventions. As a dedicated educator, she has taught undergraduate and graduate students, instilling in them the principles of basic nutrition, clinical dietetics, and community health. Her expertise extends to laboratory techniques such as PCR and cell culture, which she has applied to translational nutrition studies. Beyond academia, she has actively participated as a reviewer for prestigious international journals, shaping the quality of published science in her field. Her professional journey reflects a balance of teaching, research, community service, and scientific leadership.

Research Interests

Dr. Fatemeh Shirani’s research interests lie at the intersection of nutrition, epidemiology, and chronic disease management. She is deeply invested in exploring obesity and weight-loss strategies, nutritional interventions for diabetes and metabolic disorders, and the role of diet in preventing cardiovascular disease. Her work also investigates the emerging field of “infectobesity,” examining the connections between viral infections and obesity. By employing systematic reviews, meta-analyses, and clinical trials, she provides high-quality evidence that informs dietary recommendations and policy guidelines. Her studies not only address the biological mechanisms of nutrition-related diseases but also emphasize the translation of findings into practical interventions for populations at risk.

Awards

Dr. Fatemeh Shirani has been widely recognized for her contributions to nutritional sciences, particularly her ability to merge clinical expertise with public health perspectives. Her nomination for the Women Researcher Award reflects her outstanding achievements in advancing women’s representation in scientific leadership and her sustained impact on global nutrition research. She has consistently demonstrated excellence through her publications, conference presentations, and active participation in national and international nutrition societies. This recognition highlights not only her scientific accomplishments but also her commitment to mentoring young researchers and fostering collaborative networks across borders.

Publication

Dr. Fatemeh Shirani has produced a rich body of work that has been widely cited in international literature. Selected publications include:

Title: Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases incidence: a systematic review and meta-analysis
Journal: Nutrition
Published on: 2013
Citation: 482

Title: The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta‐analysis of randomized controlled trials
Journal: Obesity Reviews
Published on: 2016
Citation: 308

Title: Effects of Dietary Approaches to Stop Hypertension (DASH) diet on some risk for developing type 2 diabetes: a systematic review and meta-analysis on controlled clinical trials
Journal: Nutrition
Published on: 2013
Citation: 288

Title: The role of magnesium in sleep health: a systematic review of available literature
Journal: Biological Trace Element Research
Published on: 2023
Citation: 104

Title: Is phase angle a valuable prognostic tool in cancer patients’ survival? A systematic review and meta-analysis of available literature
Journal: Clinical Nutrition
Published on: 2021
Citation: 98

Title: Vinegar consumption can attenuate postprandial glucose and insulin responses; a systematic review and meta-analysis of clinical trials
Journal: Diabetes Research and Clinical Practice
Published on: 2017
Citation: 95

Title: Effects of concentrated pomegranate juice on subclinical inflammation and cardiometabolic risk factors for type 2 diabetes: A quasi-experimental study
Journal: International Journal of Endocrinology and Metabolism
Published on: 2016
Citation: 55

Conclusion

In conclusion, Dr. Fatemeh Shirani stands as a leading figure in nutritional sciences whose contributions have advanced both research and practice in the prevention and management of chronic diseases. Her ability to translate complex scientific findings into practical dietary strategies has had a lasting impact on public health. With her strong publication record, global collaborations, and dedication to mentorship, she exemplifies the qualities of an outstanding woman researcher. Her nomination for the Women Researcher Award reflects not only her academic excellence but also her leadership, vision, and commitment to improving health outcomes through nutrition science.